BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10236 related articles for article (PubMed ID: 15988909)

  • 21. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic T-lymphocyte-associated antigen-4.
    Hodi FS
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic cancer vaccines.
    Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
    Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new era in anticancer peptide vaccines.
    Perez SA; von Hofe E; Kallinteris NL; Gritzapis AD; Peoples GE; Papamichail M; Baxevanis CN
    Cancer; 2010 May; 116(9):2071-80. PubMed ID: 20187092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor immunotherapy in melanoma: on the dawn of a new era?
    Wilcox R; Markovic SN
    Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune suppression in the tumor microenvironment.
    Gajewski TF; Meng Y; Harlin H
    J Immunother; 2006; 29(3):233-40. PubMed ID: 16699366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunology and breast cancer: therapeutic cancer vaccines.
    Curigliano G; Rescigno M; Goldhirsch A
    Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming immunological tolerance to melanoma: Targeting CTLA-4.
    Hodi FS
    Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S16-23. PubMed ID: 20482528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multipeptide vaccination in cancer patients.
    Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
    Keilholz U
    J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Active immunization against cancer cells: impediments and advances.
    Velders MP; Schreiber H; Kast WM
    Semin Oncol; 1998 Dec; 25(6):697-706. PubMed ID: 9865683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA vaccines for cancer.
    Boyd D; Hung CF; Wu TC
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 512.